Carole Faig is an experienced public and private company board member and leader. During her tenure as Ernst & Young’s (EY’s) U.S. Health Leader, she spearheaded the development and execution of strategies to grow EY’s healthcare practice, which expanded to $600 million and achieved significant brand recognition.

Additionally, during her career at EY, Ms. Faig was an audit partner serving health systems, health insurers, biotech and medtech companies. She is qualified to serve as a financial expert under SEC / NYSE / NASDAQ rules and retired from EY in 2021, with more than 38 years of audit and public accounting experience.

Ms. Faig is currently a board member of Henry Schein (HSIC), a Fortune 500 and S&P 500 company, and serves on the boards of two private VC/PE-backed companies, Affinia Therapeutics and QuVa Pharma, as well as PATH, a non-profit organization dedicated to global health equity.

Throughout her career, Ms. Faig has been a champion of diversity and inclusiveness, serving on EY’s Gender Equity Task Force and receiving the EY Chairman’s Value Award and the EY Americas Assurance Inclusive Leadership Award for her efforts.

Ms. Faig earned her bachelor’s degree in accounting from Sam Houston State University and is a CPA.